Study of EDP1867 for moderate atopic dermatitis, moderate psoriasis, and/or mild asthma

 

The company Evelo Biosciences, Inc is enrolling patients into the clinical trial investigating EDP1867 in Healthy Participants and Participants With Moderate Atopic Dermatitis and, Optionally, Moderate Psoriasis, and/or Mild Asthma.

This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.

The trial is designed to enroll male and female 18 Years to 65 Years and is being conducted in the MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom; Medicines Evaluation Unit (MEU), Manchester, Greater Manchester, United Kingdom; MAC Clinical Research, Blackpool, Lancashire, United Kingdom; MAC Clinical Research, Liverpool, Merseyside, United Kingdom; MAC Clinical Research, Cannock, South Staffordshire, United Kingdom; MAC Clinical Research, Stockton-On-Tees, Teeside, United Kingdom; MAC Clinical Research, Leeds, West Yorkshire, United Kingdom.

The study start date is February 23, 2021.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT04927195

Clinical Research News

Upcoming Clinical Trials